Still a Cause for Concern
Environmental Health Perspectives v.108, n.7, Jul00
Janet Kielhorn,1 Christine Melber,1 Ulrich Wahnschaffe,1 Antero Aitio,2 and Inge Mangelsdorf1
1Fraunhofer Institute for Toxicology and Aerosol Research with Drug Research and Clinical Inhalation, Hanover, Germany; 2International Programme on Chemical Safety, World Health Organization, Geneva, Switzerland
Vinyl chloride (VC) is both a known carcinogen and a regulated chemical, and its production capacity has almost doubled over the last 20 years, currently 27 million tons/year worldwide. According to recent reports it is still a cause for concern. VC has been found as a degradation product of chloroethylene solvents (perchloroethylene and trichloroethylene) and in landfill gas and groundwater at concentrations up to 200 mg/m3 and 10 mg/L, respectively. Worldwide occupational exposure to VC still seems to be high in some countries (e.g., averages of approximately 1,300 mg/m3 until 1987 in one factory), and exposure may also be high in others where VC is not regulated. By combining the most relevant epidemiologic studies from several countries, we observed a 5-fold excess of liver cancer, primarily because of a 45-fold excess risk from angiosarcoma of the liver (ASL). The number of ASL cases reported up to the end of 1998 was 197 worldwide. The average latency for ASL is 22 years. Some studies show a small excess risk for hepatocellular carcinoma, and others suggest a possible risk of brain tumors among highly exposed workers. Lung cancer, lymphomas, or leukemia do not seem to be related to VC exposure according to recent results. The mutation spectra observed in rat and human liver tumors (ASL and/or hepatocellular carcinoma) that are associated with exposure to VC are clearly distinct from those observed in sporadic liver tumors or hepatic tumors that are associated with other exposures. In rats, the substitution mutations found at A:T base pairs in the ras and p53 genes are consistent with the promutagenic properties of the DNA adduct 1,N6-ethenoadenine formed from VC metabolites. Risk assessments derived from animal studies seem to overestimate the actual risk of cancer when comparing estimated and reported cases of ASL. Key words: angiosarcoma of the liver (ASL), landfill leachate, liver cancer, occupational exposure, risk assessment, vinyl chloride. Environ Health Perspect 108:579-588 (2000). [Online 2 June 2000]
Address correspondence to J. Kielhorn, Fraunhofer Institute for Toxicology and Aerosol Research, Nikolai-Fuchs Straße 1, D-30625 Hanover, Germany. Telephone: 49 (511) 5350 329. Fax: 49 (511) 5350 335. E-mail: email@example.com
This paper is based on work performed by the authors in preparation of the International Programme on Chemical Safety (IPCS) draft document on vinyl chloride. This paper is the sole responsibility of the authors.
IPCS Task Group members were A. Barbin, V. Feron, P. Heikkila, J. Kielhorn, M. Kogevinas, H. Malcolm, W. Pepelko, A. Pinter, L. Simonato, H. Vainio, E. Ward, and J. Zielinski.
We acknowledge the financial support of the German Federal Ministry for the Environment, Nature Conservation and Nuclear Safety.
Received 23 December 1999; accepted 8 March 2000.
Vinyl chloride (VC) is one of the best-studied chemicals. Because of evidence that VC was carcinogenic in both animal studies and in human case reports in the early 1970s, there were drastic changes in the production methods and in occupational hygiene in the VC/polyvinyl chloride (PVC) industry in the Western World, with the closure of some factories that were not able to conform to the strict regulations and occupational exposure limits. VC levels in PVC resins and products were also restricted. As a result of the strict occupational exposure limits, no cases of angiosarcoma of the liver (ASL), the rare tumor associated with VC exposure, have been reported in new workers exposed to VC in those factories since that time. It seemed that the VC problem had been solved and the story committed to the toxicologic history books. But recent epidemiologic, environmental, and biomechanistic findings have opened up new aspects of this chemical. VC has recently been evaluated by an international interdisciplinary task group; this paper highlights these recent developments, which are presented in more detail in the International Programme on Chemical Safety (IPCS) Environmental Health Criteria document on VC (1). VC remains a cause for concern because potential exposure to this chemical and new cases of ASL are still being reported.
VC was first used commercially in the 1920s, but it was not until the 1930s that techniques were devised to polymerize VC into stable forms of PVC. Polymerization is a batch process and takes place in a reactor (autoclave) under controlled conditions. Once the polymerization has ended, VC is emptied into degassing tanks. The reactor has to be cleaned periodically because a film of PVC forms on the inside wall of the reactor. Although this is now performed with solvents or automatic high-pressure jets, previously this task was a manual process requiring workers to use spatulas or hammers and chisels; the workers were exposed to high concentrations of VC up to 1,000 ppm (2,600 mg/m3) and possibly even higher peaks of exposure. As a result, some of these workers suffered from a specific pathologic syndrome called "vinyl chloride disease," with symptoms including earache and headache, dizziness, unclear vision, fatigue and lack of appetite, nausea, sleeplessness, breathlessness, stomachache, pain in the liver/spleen area, pain and tingling sensation in the arms/legs, cold sensation at the extremities, loss of libido, and weight loss (2). Clinical findings included scleroderma-like changes in the fingers, with subsequent bony changes in the tips of the fingers described as acro-osteolysis; peripheral circulatory changes similar to Raynaud's phenomenon; and enlargement of the liver and spleen, with a specific histologic appearance and respiratory manifestations (3-6).
After the case series on hepatic angiosarcoma among workers exposed to vinyl chloride (7) was published in 1974, several further case series and small epidemiologic studies, primarily with emphasis on hepatic tumors, were published in the 1970s and 1980s (8-28). These reports showed that exposure to high levels of VC were associated with the incidence of ASL. Other (non-ASL) cancer sites and types that may be connected with VC exposure include tumors of the liver (e.g., non-angiosarcoma), particularly hepatocellular carcinoma; respiratory system; digestive system other than the liver; lymphopoietic and hematopoietic tissue; brain and other central nervous system; and malignant melanoma.
Parallel to human case reports, after the first reports of the carcinogenicity of VC in rats (29,30), extensive studies were carried out in the rat, mouse, and hamster on the effects of oral (31-33) and inhalation (34-37) exposure to VC. These studies have shown that VC is both genotoxic and carcinogenic, causing a wide spectrum of tumors in various animal species. Tumors that have been been found, at least in animal species, include ASL and other liver tumors, mammary gland carcinoma, neuroblastoma, nephroblastoma, forestoamach and lung tumors, and Zymbal gland tumor. Non-neoplastic effects include reduced body weight and increased relative spleen weight, hepatocellular degeneration, proliferation of cells lining the liver sinusoids, degenerative alteration in the testis, tubular nephrosis, and focal degeneration of the myocardium in rats (38,39).
New Aspects of VC
VC has a world capacity of about 27 million tons/year worldwide, almost double the production in 1980 (Table 1), and is produced in most industrial countries. Five percent of this VC goes into the production of chlorinated solvents, primarily 1,1,1-trichloroethane (10,000 tons/year). Most (95%) VC produced is further polymerized under varying conditions to produce PVC.
Table 1 - World PVCa Production/Capacity 1980-1998
VC Environmental Contamination and Remediation
Reports from several countries (43-59) recently showed high levels of VC contamination in soil, groundwater, aquifers, and wells near landfill and industrial waste disposal sites that were not located near VC/PVC production facilities. VC concentrations were up to 12 mg/L in some groundwater samples and up to 230 mg/m3 in landfill gas samples (Table 2). VC can be formed microbially, under anaerobic conditions, from the reductive dehalogenation of the more highly chlorinated chloroethenes: perchloroethylene (PCE), trichloroeathene (TCE), and the dichloroethene isomers, cis-1,2-dichloroethene (cis-1,2-DCE), trans-1,2-DCE, and 1,1-DCE (Figure 1) (59-62). PCE and TCE are used as industrial solvents for degreasing and cleaning metal parts and electronic components and in dry cleaning. Careless handling, storage, and disposal, as well as the high chemical stability of these compounds, have made them, and consequently VC, some of the most frequently encountered groundwater contaminants. Although VC may be further degraded to less and nonchlorinated ethenes and possibly finally to carbon dioxide and ethane, this proceeds at a slow rate under highly reducing conditions (63-65); as a consequence, there can be a build-up of VC in landfills and surrounding areas.
Figure 1. Microbial degradation of chlorinated ethenes to form vinyl chloride.
Several field studies of PCE/TCE-contaminated landfill sites and aquifers (61,66-70) have shown that, under specific conditions, PCE and TCE can be intrinsically biodegraded anaerobically to ethene by indigeneous methanogenic, acetogenic, and sulphate-reducing bacteria. Also, under aerobic conditions there is a potential for direct or cometabolic oxidation of DCE and VC. Because each site has individual conditions (e.g., the presence of other solvents such as acetone and methanol), the degradation rates cannot be directly compared. In one study, half-lives of 1-2 years have been estimated for each stage in the reaction chain (e.g., DCE to VC; VC to ethene) (49). In general, except under specific conditions, there is little biodegradation of VC.
The awareness of this problem of VC formation has encouraged the development of in situ bioremediation of chlorinated solvents and VC using anaerobic or aerobic cometabolic processes (72-74).
Several laboratories are now attempting to isolate strains of bacteria that can completely dehalogenate cis-DCE or VC to ethene. Although no known microorganism can aerobically destroy PCE, some anaerobic bacteria (e.g., Dehalobacter restrictus) use these chlorinated solvents as electron acceptors for energy conservation and growth (dehalorespiration), by breaking them down in the process to form cis-dichloroethene, although restricted diet and conditions are necessary (75,76). A coccoid bacterium has been isolated (provisionally named Dehalococcoides ethenogenes strain 195) that, together with extracts from mixed microbial cultures, can dechlorinate PCE to form cis-DCE and remove other chlorine atoms to form vinyl chloride and finally ethene (77). Meier (78) reported that quantitative mineralization of VC was possible with isolated aerobic cultures of Mycobacterium aurum under special conditions.
General Population Exposure
Exposure of the general population to VC is possible by several routes: inhalation of air polluted with VC, mainly in the vicinity of VC/PVC plants or waste disposal sites; intake of contaminated drinking water; ingestion of food, beverages, and medicaments packed in PVC; and absorption through skin from PVC-wrapped cosmetics. Normally, the general population is exposed, if at all, to only small amounts of VC. However, the exposure varies depending on the regulatory measures of each country, the occurrence of accidents, or the spread of precursor substances.
After an accident in Schönebeck, Germany, in June 1996, which involved the derailment of a train carrying VC and the subsequent fire, 325 persons were documented as having acute symptoms, but these correlated with exposure to the pyrolytic products (e.g., hydrochloric acid) and not to VC itself. Over 1,000 tons of VC were involved, of which approximately 250 tons burned and 350 tons were reclaimed after the fire. One hundred fifty tons of HCl were released (79). According to measurements first taken 14 hr after the fire, the maximum concentrations of VC were approximately 80 mg/m3 near the train and 25 mg/m3 at 200 m from the center of the fire (80). In a study of 29 individuals exposed as a result of this accident, there was a significant increase in chromosomal abberrations as compared to an unexposed control group (81).
With the improvement in industrial hygiene and stricter emission controls in many countries, the general population is not usually exposed to emissions from VC and PVC production facilities, but there are exceptions. For example, Zhao et al. (82) reported that, in China, workers and their families were exposed to VC because the dormitories were near or even on the campus of the PVC/VC plant. In 1988, maximum and mean daily concentrations of 12.7 and 4.4 mg/m3, respectively were measured in dormitories 50 m away from the plant (82).
Occupational Exposure Levels
Industrial environments associated with VC exposure include VC production plants, VC polymerization (PVC production) plants, and PVC processing factories. For example, the number of workers exposed to VC has been estimated to be approximately 80,000 in the United States (1981-1983) (83) and > 5,000 in Sweden (1975-1980) (84). Because VC was not recognized as a toxic compound at the beginning of VC/PVC production in the United States and Western Europe, no precautions were taken against contact and no regular workplace monitoring was performed. Therefore, only sporadic measurements or retrospective estimates of exposures are available for the period before 1975 (Table 3). Some VC workers, autoclave cleaners in particular, were estimated to be exposed to as much as 1,000 ppm (2,600 mg/m3) in the 1950s and earlier (85-89). The exposure was reduced to one-tenth of this by the mid-1970s. After 1975, levels were usually < 1-5 ppm (< 2.6-13 mg/m3) in many countries.
In many countries, factories that could not reduce the emissions of VC to satisfy the rigorous laws in the early 1970s were forced to close. In other countries, this was not possible for socioeconomic reasons; thus, large factories with old-fashioned technologies continued the manufacturing process (90) and workers continued to be exposed to high levels of VC (Table 4).
Recent data from Croatia may reflect the actual conditions still prevalent in some countries. A retrospective investigation of the exposure to VC has been performed in 37 autoclave workers in Split, Croatia, who were maximally exposed to the emission of VC by the nature of their job (emptying and cleaning) in a suspension polymerization plant. The investigation covered the period from 1969 to 1987, after which the factory was closed due to the high emission of VC. Data show that the 37 workers were exposed over this period to average VC concentrations of approximately 500 ppm (1,300 mg/m3) (90,92). As a consequence of this high exposure to VC, a disproportionately large number of ASL mortalities have been reported in Croatia (Table 5).
Angiosarcoma of the Liver
ASL, also known as hemangioendothelial sarcoma, is an extremely rare liver tumor and is difficult to diagnose. ASL constitutes only 2% of all primary tumors of the liver in the general population; for example, from 1975-1987 figures in England and Wales, there was an annual incidence of 1.4 cases/10 million people (101). ASL has been associated only with exposure to VC, Thorotrast (a contrast medium used in X-ray radiography in the 1930s-1950s), and arsenic (7,102). There are only a few instances where the diagnosis of a rare tumor enables the identification of a risk without having to rely on large epidemiologic studies. Furthermore, cases of ASL in VC workers could be directly attributable to exposure to VC. Regular international surveillance of cases of ASL from VC exposure shows that 118 cases were registered in 1985 (103), 173 in 1993 (104) and 197 up to the end of 1999 (105) (Table 5). The average latent period between starting work in an occupation involving VC exposure and the ASL diagnosis or death for 99 cases was 22 years (87,106). Because of this long latency, tumors are still detected although the exposure has ceased or has been considerably reduced. ASL seems to be associated only with high exposure to VC.
Abdominal pain, weakness, fatigue, and weight loss are the most prominent clinical symptoms, and hepatosplenomegaly, ascites, and jaundice are the most common clinical signs. Remarkably, except for the final stages, there seems to be little impairment of hepatic function in ASL patients (106). Any treatment is generally unsuccessful, and survival after diagnosis usually averages < 12 months. Hepatic failure and intra-abdominal hemorrhage are the usual terminal effects (104,107). Liver transplantation might be the only chance of survival (108). Surgical resection and adjuvant chemotherapy have been suggested if ASL is detected early enough (109-111).
Epidemiologic Studies on VC/PVC Workers
From the data on health surveillance and mortality records of VC workers and the easy correlation of ASL with VC exposure, there have been numerous case reports, cohort studies, and epidemiologic studies on VC/PVC workers from many countries. But because there are only estimates of levels of VC exposure before the mid-1970s, there are not enough data in many cases to estimate an exposure-response relationship.
Two larger studies combined earlier studies from the United States (112) and Europe (113) and updated the mortality follow-up. These studies have been or are currently being updated again (114,115).
Wong et al. (112) updated earlier U.S. studies (8,9) and subsumed others (10-15). The cohort included 10,173 men who had worked for at least 1 year in jobs involving VC exposure in 37 plants in the United States before January 1973. The observation covered 1942-1982, and the authors compared the observed mortality to the expected rates, based on U.S. national rates for white males, standardized for age, and calendar time. In an attempt to characterize historical exposures, Wong et al. (112) graded individual jobs and job locations by each company as "high," "medium," or "low"; this approach failed because of differences of interpretation of the terms into parts-per-million levels. The actual levels of exposure are not known.
The second large cohort study, by Simonato et al. (113), updated several earlier European cohorts (16-22,96), and comprised a total of 14,351 subjects from 19 factories. After exclusion of short-term employees (< 1 year), females, deaths outside the observation period, and members of more than one cohort, 12,706 subjects remained for the analysis. The follow-up was 97.7% complete, and the average length of follow-up was 17 years, giving a total number of 222,746 person-years. National rates of mortality, specific for age and 5-year calendar periods were used for the comparison. The observation period was different for different factories. In most cases, the observation period began in 1955 and extended to 1986. Calendar period-specific job exposure matrices were developed for 13 of the 19 factories. These job exposure matrices were developed using the job title as basic unit in which exposure was assessed. Estimates of exposure were assigned a priori by a group of industrial hygienists on the basis of the historical information available from the companies.
Four smaller prospective studies on VC exposure workers have been conducted in Canada (23), Germany (24,25), France (26,27) and the former Soviet Union (28).
IPCS Task Group Findings
The IPCS Task Group (1) reported that "there is a 5-fold excess risk for liver cancer observed among workers exposed to VC"; this occurs primarily in PVC polymerization factories, where the highest exposures to VC occur (Table 6). Much of the excess risk can be attributed to the excess risk for ASL. In the European study, Simonato et al. (113) found a 45-fold excess risk for ASL in workers exposed to VC > 10,000 ppm-years as compared to workers exposed to < 2,000 ppm-years (Table 7). In the European study, there was histopathologic confirmation of type of liver cancer for 17 out of 24 liver cancers; of those confirmed, 16 were ASL. In the U.S. study, Wong et al. (112) registered 21 out of 37 liver cancer deaths as ASL. In the Canadian study, Thériault and Allard (23) reported that all 8 of the liver cancer deaths were ASL; this was also the case for the 3 liver cancer deaths reported in the French study by Laplanche et al. (27). There is no information about whether liver cancers were ASL in the German study by Weber et al. (24), and in the Russian study, Smulevich (28) reported no diagnosed liver cancers. Some ASL cases in VC-exposed workers have probably remained undiagnosed; the causes of these deaths may have been recorded on death certificates as unspecified liver cancers or other liver-associated disease.
The risk for hepatocellular carcinoma (HCC) was examined in several studies. Simonato et al. (113), Thériault and Allard (23), and Laplanche et al. (27) did not observe an excess risk of HCC, whereas data from Wong et al. (112) in the United States and from updates of the Italian component of the European cohort (116,117) seem to indicate that there is an excess risk for HCC. The risk for HCC is not as great as the risk for ASL. It is difficult to interpret the results of these studies for HCC because of the possible inaccuracies of diagnoses of angiosarcoma and HCC based on death certificate information and because of the lack of histopathologic confirmation of liver cancer diagnoses. The IPCS Task Group (1) has determined that "although the results are not fully consistent between studies, the data suggest that there may be a small excess risk for HCC."
The IPCS Task Group (1) also reported that
Four out of five studies reporting results for brain tumours identified a moderate excess risk with [a standard mortality ratio] of 1.42 for the combined data from 5 studies (43 observed, 95% CI [confidence interval], 1.03-1.91).
The risk for brain tumors tended to increase with duration of exposure and employment in the European (113) and U.S. (112) studies. Furthermore, in the U.S. study, Wong et al. (112) reported that the highest risk occurred in the two factories where the most ASL cases had been diagnosed; these were the factories where the highest VC exposure was presumed to have occurred. In the European study in which the dose-response relationship was examined, Simonato et al. (113) observed no association of brain tumors with cumulative exposure to VC. The overall epidemiologic evidence suggests a possible risk for brain tumors among VC workers.
An increase in lung cancer among VC workers had been reported in some early studies (10). However, there was no excess risk indicated in the two largest studies--the European (113) and U.S. (112) studies--or in the other four smaller studies (23,24,27,28). No associations were found for either the duration of exposure/employment in the U.S. (112) or European (113) studies, or for cumulative exposure to VC in the European study (113).
An excess risk for malignant lymphomas was reported in some early studies (10,14,25,28), but no excess risk was observed in the two largest cohorts [the U.S. (112) and European studies (113)] or in the Canadian cohort (23). In both the Russian (28) and German (24) studies, an excess risk for leukemia and lymphoma combined was observed. It should be noted that different methods of disease classification were used and sometimes lymphomas were grouped with malignant myelomas. The overall results of these studies do not show any significant increased risk for lymphomas or leukemia.
Since the IPCS Task Group meeting in January 1999 in Hanover, Germany, the update of the study by Wong et al. (112) has been completed (114). Specific cancers that showed meaningful excesses both through 1982 and through 1995 included cancers of the liver and the biliary tract (mostly due to a large excess of deaths due to ASL), the brain, and the connective and soft tissues. Of several causes of death previously believed to be related to VC exposure, no excesses were observed; these include lung cancer, cancers of lymphatic and hematopoietic tissue, emphysema and pneumoconioses, and other lung diseases, including chronic obstructive pulmonary disease.
VC Initiation of Hepatocarcinogenesis
Carcinogenesis is a multistep process. In the last few years, progress has been made in the understanding of a possible mechanism of initiation of hepatocarcinogenesis by VC. Recent studies (1,118-121) indicate that VC acts as a genotoxic carcinogen. After metabolic activation of VC into chloroethylene oxide (CEO) by cytochrome P450 isozyme 2E1 (CYP2E1), it exerts various genotoxic effects (including gene mutations and chromosomal aberrations) in different organisms, including bacteria, yeasts, mammalian cells in culture, Drosophila, rodents, and humans [reviewed by Giri (122) and updated by the IPCS (1)]. Among the mutagenic events induced by VC, base pair substitutions appear to be the most frequent (118).
In vitro studies have demonstrated that CEO and chloroacetaldehyde can alkylate nucleic acid bases (Figure 2) (1,118,119,123). 7-(2´-Oxoethyl)guanine, the major DNA adduct formed by VC and CEO, does not exhibit promutagenic properties. In contrast, four minor adducts, 1,N6-ethenoadenine (A), 3,N4-ethenocytosine (C), N2,3-ethenoguanine (N2,3-G), and 1,N2-ethenoguanine (1,N2-G), show promutagenic properties, inducing mainly base pair substitutions and a low level of frameshift mutations (124). Site-specific mutagenesis studies in Escherichia coli and in mammalian cell lines have shown that both G and C can induce G:C A:T transitions; C can also lead to C:G A:T transversions (125,126). A can induce misincorporation of G, C, or A during replication, thus inducing the base-pair subsatititions A:T C:G, A:T G:C, or A:T T:A (127,128).
Figure 2. Vinyl chloride reactive metabolites and nucleic acid adducts formed from them in vivo [adapted from Ciroussel et al. (123)].
7-(2´-Oxoethyl)guanine and three etheno adducts (A; C; and N2,3-G; Figure 2) have been detected in DNA from rats and mice exposed to VC (123,128-131). Highly variable background levels of A and C were found in all the tissues examined (132,133). After exposure of rats to VC, significantly elevated levels of A and C were measured in most tissues, except the brain; there were also no significant increases of A levels in the kidney and spleen (121,134).
The liver is one of the primary targets for VC-induced carcinogenesis in rats and humans. Mutations have been found in liver tumors associated with VC exposure. Mutations, all A:T T:A transversions, have been described in the p53 gene in three human ASL cases (Table 8). In human ASL, the Ki-ras gene is also activated through a G:C A:T mutation at base 2 of codon 13 (Table 9). Ki-ras gene activation has not been found in rat ASL (141,142). However, 44% of rat ASL cases were found to contain a mutated p53 gene: most mutations were base pair substitutions that involved mainly A:T base pairs (137). The data suggest the existence of hot spots for mutations in the p53 gene; one mutation found in two rat ASL cases was equivalent to the same mutation characterized in one human ASL case associated with VC exposure. In rat HCC induced by VC, the Ha-ras gene is activated through an A:T T:A transversion in codon 61 (Table 9).
The mutation spectra observed in liver tumors (ASL and/or HCC) that are associated with VC exposure in humans and rats are clearly distinct from those observed in sporadic liver tumors or in hepatic tumors associated with other exposures. In rats, the substitution mutations found at A:T base pairs in the ras and p53 genes are consistent with the promutagenic properties of A and with the accumulation and persistence of this lesion in hepatic DNA (121). Altogether, available data suggest that etheno adducts could be involved in the initiation of hepatocarcinogenesis by VC.
Analysis of Dose Response
VC has been shown to be carcinogenic and toxic in both oral and inhalation experimental bioassays, as well as in human epidemiologic studies. For VC, dose-response analyses have been based on data of ASL because it is the most critical and sensitive effect.
The bioassays that have most often been used as the basis for dose-response analysis in animals are the rat inhalation studies of Maltoni et al. (34,35) (involving a wide range of exposure levels and a large number of animals) and the oral studies of Feron et al. (31) and Til et al. (32,33). Risk evaluations derived from animal data can be compared with human epidemiologic data on ASL [e.g., Simonato et al. (113)].
Risk Assessment Based on Human Epidemiologic Data
Simonato et al. (113) performed a regression analysis from epidemiologic data to assess the relative risk of liver cancer and ASL in occupational exposure to VC using the variables cumulative exposure (ppm-years) and years since first employment. On the basis of this regression analysis, Simonato et al. (113) calculated the absolute risk of ASL per 100,000 (Table 7). For example, for workers exposed for > 25 years to < 80 ppm (i.e., < 2,000 ppm-years), there is a risk of 6.2 as compared to those who are exposed for only a few years at the same exposure level. At higher exposure levels (2,000-5,999 ppm-years), the risk increases to 42.2.
Physiologically Based Pharmacokinetic Model
In order to perform quantitative risk assessment using animal bioassays, physiologically based pharmacokinetic models (PBPKs) have been developed to derive the concentration of active metabolite at the critical target site, the liver, and to extrapolate this from animals to humans. The PBPK model should be validated by taking into account the known metabolic pathways and by using experimentally determined metabolic constants.
Clewell et al. (143) developed a model in which the initial metabolism of VC was hypothesized to occur via two saturable pathways (one representing high-affinity, low-capacity oxidation by CYP2E1 and one representing low-affinity, high-capacity oxidation by other P450 isozymes), producing CEO as an intermediate product in both cases. Chloroacetaldehyde (from CEO) was modeled as the major substrate of glutathione conjugation, with a lesser amount of CEO as the substrate of glutathione S-epoxide transferase. The model was similar to that proposed by Chen and Blancato (144) with regard to number and type of compartments, physiologic parameters, and the assumption that metabolism of VC takes place only in the liver; the authors used partition coefficients from the literature (145). The metabolic parameters for the two oxidative pathways were estimated from gas uptake experiments (146); in this model, it was assumed that the reactive VC metabolites further degrade to carbon dioxide, react with glutathione, or react with cellular macromolecules. Parameters for subsequent metabolism were taken from the PBPK model for vinylidene chloride (147).
This PBPK model (143) was used to predict the total production of reactive metabolites from VC in the animal bioassays and in human exposure scenarios. These measures of internal exposure were then used in the linearized multistage model (LMS) (148) to predict the risk associated with lifetime exposure to VC in air or drinking water.
Risk Assessments Based on Animal Studies
Inhalation Exposure Studies
The 95% upper confidence limit for excess lifetime risk associated with continuous inhalation of 1 µg/m3 of VC is 8.4 µg/L 10-5 in the current U.S. Environmental Protection Agency (U.S. EPA) health effects assessment summary tables (HEAST) (149), which are currently being updated. This is based on the studies of Maltoni et al. (34), but not using a PBPK model.
Reitz et al. (150) developed a PBPK model based on the study of Maltoni et al. (34), but using a single saturable pathway to predict the measures of delivered dose in rats. Reitz et al. (150) calculated lifetime average daily doses and fit them to an empirical dose-response model (a linearized multistage model). The 95% upper confidence limits for excess lifetime risk associated with continuous inhalation of 1 µg/m3 VC calculated from this PBPK-based approach was 5.7 10-7. Thus, the value calculated using the PBPK model differs from the HEAST risk estimation [8.4 µg/L 10-5 (149)] by two orders of magnitude.
Reitz et al. (150) then compared their predictions of ASL incidences in humans with different exposures to those reported by Simonato et al. (113). For example, in the subgroup that Simonato et at. (113) estimated to have the lowest exposures (0-2,000 ppm-years), the reported incidence of ASL was 6.2/100,000 (Table 7). In contrast, Reitz et al. (150) calculated a maximum likelihood estimate of 188-736 cases/100,000 for exposures of 500-2,000 ppm-years. Thus, this risk assessment (150) using a PBPK model predicted almost two magnitudes more liver cancer cases than were actually reported.
Oral Exposure Studies
The present HEAST (149), which uses results from the rat bioassay of Feron et al. (31), gives a slope factor of 1.9 per mg/kg/day and an oral unit risk of 5.4 µg/L 10-5. These values are based on the U.S. EPA evaluations of 1984 and 1985 for which a PBPK model was not used. These values are under review and are subject to change.
By using results from the rat bioassay of Til et al. (32) and by applying the linearized multistage model, the human lifetime exposure for a 10-5 excess risk of ASL was calculated to be 20 µg/day (151). In this report, it was assumed that, in humans, the number of cancers at other sites may equal that of ASL, so that a correction (factor of 2) for cancers other than ASL is justified. VC concentrations in drinking water of 5 µg/L were calculated as being associated with excess risks of 10-5.
VC is a chemical of interest in many fields of study. Workers in some parts of the world were and may still be exposed to high levels of VC, although it is a known carcinogen and is regulated in many countries. Fortunately, it seems that ASL is correlated with only high exposures over long periods. Because ASL has a latency of approximately 20 years, mortality from ASL caused by VC exposure is still to be expected in the next few years. With further improvements in industrial hygiene in countries all over the world, perhaps VC-induced ASL mortalities will become a phenomenon of the past.
The detection of VC as a degradation product of some chlorinated solvents is an indication of the intricate problems that may be attributed to past and future chemical waste deposits. Progress in remediation processes should be able, at least in part, to resolve these problems.
Research into the mechanisms of carcinogenesis has been initiated because ASL is a rare tumor and its occurrence in VC workers can be correlated with estimated VC exposure. Studies into mutation spectra observed in rat and human liver tumors (ASL and/or HCC) have shown that etheno adducts, in particular 1,N6-ethenoadenine (A), have promutagenic properties and are responsible for substitution mutations found at A:T base pairs in the ras and p53 genes.
Since the 1970s it has been possible to monitor exposed VC workers and to keep records of mortality cases; a large amount of data is now available for epidemiologic studies, which are being continually updated. Using animal studies and various models, researchers have attempted to predict the risk of mortality and to extrapolate predictions from animals to humans. By comparing these predictions with human ASL mortality records, current risk assessment methodology can be validated.
References and Notes
1. WHO. International Programme on Chemical Safety. Vinyl Chloride. Environmental Health Criteria 215. Geneva:World Health Organization, 1999.
2. Thiess AM, Versen P. Occupational medical thoughts on the so-called 'vinyl chloride disease' [in German]. Arbeitsmed Sozialmed Präventivmed 7:146-148 (1974).
3. Lange C-E, Jühe S, Stein G, Veltman G. The so-called vinyl chloride disease-an occupationally caused systemic sclerosis [in German]. Int Arch Arbeitsmed 32:1-32 (1974).
4. Suciu I, Prodan L, Ilea E, Paduraru A, Pascu L. Clinical manifestations in vinyl chloride poisoning. Ann NY Acad Sci 246:53-69 (1975).
5. Veltmann G, Lange CE, Jühe S, Stein G, Bachner U. Clinical manifestations and course of vinyl chloride disease. Ann NY Acad Sci 246:6-17 (1975).
6. Lelbach WK, Marsteller HJ. Vinyl chloride-associated disease. Adv Intern Med Pediatr 47:1-110 (1981).
7. Creech JL, Johnson MN. Angiosarcoma of liver in the manufacture of polyvinyl chloride. J Occup Med 16:150-151 (1974).
8. Tabershaw IR, Gaffey WR. Mortality study of workers in the manufacture of vinyl chloride and its polymers. J Occup Med 16:509-518 (1974).
9. Cooper WC. Epidemiologic study of vinyl chloride workers: mortality through December 1, 1972. Environ Health Perspect 41:101-106 (1981).
10. Monson RR, Peters JM, Johnson MN. Proportional mortality among vinyl chloride workers. Environ Health Perspect 11:75-77 (1975).
11. Nicholson WJ, Hammond EC, Seidman H, Selikoff IJ. Mortality experience of a cohort of vinyl chloride-polyvinyl chloride workers. Ann NY Acad Sci 246:225-230 (1975).
12. Ott MG, Langner RR, Holder BH. Vinyl chloride exposure in a controlled industrial environment. Arch Environ Health 30:333-339 (1975).
13. Duck BW, Carter JT, Coombes EJ. Mortality study of workers in a polyvinyl-chloride production plant. Lancet 13:1197-1199 (1975).
14. Waxweiler J, Falk H, McMichael A, Mallov JS, Grivas AS, Stringer WT. A cross-sectional epidemiologic survey of vinyl chloride workers. Publication No 77-177. Cincinnati, Ohio:U.S. Department of Health, Education, and Welfare, 1977.
15. Buffler PA, Wood S, Eifler C, Suarez L, Kilian DJ. Mortality experience of workers in a vinyl chloride monomer production plant. J Occup Med 41:195-203 (1979).
16. Byrén D, Engholm G, Englund A, Westerholm P. Mortality and cancer morbidity in a group of Swedish VCM and PVC production workers. Environ Health Perspect 17:167-170 (1976).
17. Fox AJ, Collier PF. Mortality experience of workers exposed to vinyl chloride monomer in the manufacture of polyvinyl chloride in Great Britain. Br J Ind Med 34:1-10 (1977).
18. Molina G, Holmberg B, Elofsson S, Holmlund L, Moosing R, Westerholm P. Mortality and cancer rates among workers in the Swedish PVC processing industry. Environ Health Perspect 41:145-151 (1981).
19. Storetvedt HS, Langard SL, Andersen AA. Incidence of cancer among vinyl chloride and polyvinyl chloride workers: further evidence for an association with malignant melanoma. Br J Ind Med 44:278-280 (1987).
20. Jones JH. Worker exposure to vinyl chloride and poly(vinyl chloride). Environ Health Perspect 41:129-136 (1981).
21. Belli S, Bertazzi PA, Comba P, Foa V, Maltoni C, Masina A, Pirastu R, Reggiani A, Vigotti MA. A cohort study on vinyl chloride manufactures in Italy: study design and preliminary results. Cancer Lett 35:253-261 (1987).
22. Pirastu R, Comba P, Reggiani A, Foa V, Masina A, Maltoni C. Mortality from liver disease among Italian vinyl chloride monomer/polyvinyl chloride manufacturers. Am J Ind Med 17:155-161 (1990).
23. Thériault G, Allard P. Cancer mortality of a group of Canadian workers exposed to vinyl chloride monomer. J Occup Med 23:671-676 (1981).
24. Weber H, Reinl W, Greiser E. German investigations on morbidity and mortality of workers exposed to vinyl chloride. Environ Health Perspect 41:95-99 (1981).
25. Greiser E, Reinl W, Weber H. Vinyl chloride exposure and mortality of German chemical workers in comparison to comparison of non-exposed chemical workers and PVC workers. Zentralbl Arbeitsmed Arbeitsschutz Prophyl 32:44-62 (1982).
26. Laplanche A, Clavel F, Contassot JC, Lanouziére C. Exposure to vinyl chloride monomer--report on a cohort study. Br J Ind Med 44:711-715 (1987).
27. Laplanche A, Clavel-Chapelon F, Contassot JC, Lanouziére C. Exposure to vinyl chloride monomer: results of a cohort study after a seven year follow up. Br J Ind Med 49:134-137 (1992).
28. Smulevich VB, Fedotova IV, Filatova VS. Increasing evidence of the risk of cancer in workers exposed to vinyl chloride. Br J Ind Med 45:93-97 (1988).
29. Viola PL. Pathology of vinyl chloride. Med Lav 61:147-180 (1970).
30. Viola PL, Bigotti A, Caputo A. Oncogenic response of rat skin, lungs and bones to vinyl chloride. Cancer Res 31:516-522 (1971).
31. Feron VJ, Hendriksen CFM, Speek AJ, Til HP, Spit BJ. Lifespan oral toxicity study of vinyl chloride in rats. Food Cosmet Toxicol 19:317-333 (1981).
32. Til HP, Immel HP, Feron FJ. Lifespan Oral Carcinogenicity Study of Vinyl Chloride in Rats. Division for Nutrition and Food Research TNO. TNO Report V 83.285/291099. Zeist, The Netherlands:Netherlands Organization for Applied Scientific Research, 1983;1-29.
33. Til HP, Feron VJ, Immel HR. Lifetime (149-week) oral carcinogenicity study of vinyl chloride in rats. Food Chem Toxic 29:713-718 (1991).
34. Maltoni C, Lefemine G, Ciliberti A, Cotti G, Caretti D. Carcinogenicity bioassays of vinyl chloride monomer: a model of risk assessment on an experimental basis. Environ Health Perspect 41:3-29 (1981).
35. Maltoni C, Lefemine G, Ciliberrti A, Cotti G, Carretti D. Experimental Research on Vinyl Chloride Carcinogenesis. Archives of Research on Industrial Carcinogenesis, Vol II. Princeton, NJ:Princeton Scientific Publisher Inc, 1984.
36. Drew RT, Boorman GA, Haseman JK, McConnell EE, Busey WM, Moore JA. The effect of age and exposure duration on cancer induction by a known carcinogen in rats, mice and hamsters. Toxicol Appl Pharmacol 68:120-130 (1983).
37. Lee CC, Bhandari JC, Winston JM, House WB, Dixon RL, Woods JS. Carcinogenicity of vinyl chloride and vinylidene chloride. J Toxicol Environ Health 4:15-30 (1978).
38. Sokal JA, Baranski B, Majka J, Rolecki R, Stetkiewicz J, Ivanova-Chemishanska L, Vergieva T, Antonov G, Mirkova E, Kolakowski A, et al. Experimental studies on the chronic toxic effects of vinyl chloride in rats. J Hyg Epidemiol Microbiol Immunol 24:285-294 (1980).
39. Wisniewska-Knypl JM, Klimczak J, Kolakowski J. Monooxygenase activity and ultrastructural changes of liver in the course of chronic exposure of rats to vinyl chloride. Int Arch Occup Environ Health 46:241-249 (1980).
40. Allsopp MW, Vianello G. Poly(vinyl)chloride. In: Ullmann's Encyclopedia of Industrial Chemistry: Plastics, Properties and Testing to Polyvinyl Compounds, 5th ed, Vol A21 (Elvers B, Hawkins S, Schulz G, eds). Weinheim, Germany:VCH Verlagsgesellschaft mbH, 1992;717-742.
41. Rehm T, Werner R. Polyvinylchloride [in German]. Kunststoffe 86:1474-1476 (1996).
42. European Council of Vinyl Manufacturers. Personal communication.
43. Lipsky D, Jacot B. Hazardous emissions from sanitary landfills. In: Proceedings from the 78th Annual Meeting of the Air Pollution Control Association, 16-21 June 1985, Detroit, Michigan (Air Pollution Control Association, ed). New York:Fred C. Hart Associates, 1985;1-13.
44. Ward RS, Williams GM, Hills CC. Changes in major and trace components of landfill gas during subsurface migration. Waste Manag Res 14:243-261 (1996).
45. Henning KD, Richter E. Abgas-Energie [in German]. Entsorgungspraxis 5:268-272 (1985).
46. Höfler F, Schneider J, Möckel HJ. Analytical investigations on the composition of gaseous effluents from a garbage dump. Fresenius Z Anal Chem 325:365-368 (1986).
47. Janson O. Characterisation of landfill gases through trace substances in particular sulphur compounds [in German]. Müll Abfall 4:198-208 (1989).
48. Bruckmann P, Mülder W. The content of organic trace substances in landfill gases [in German]. Müll Abfall 12:339-346 (1982).
49. Allen MR, Braithwaite A, Hills CC. Trace organic compounds in landfill gas at seven U.K. waste disposal sites. Environ Sci Technol 31:1054-1061 (1997).
50. Köster M. Occurrence, evaluation and analysis of vinyl chloride as a degradation product of chlorinated ethenes in contaminated areas [in German]. GWF-Wasser/Abwasser 130:694-697 (1989).
51. Sabel GV, Clark TP. Volatile organic compounds as indicators of municipal solid waste leachate contamination. Waste Manag Res 32:119-130 (1984).
52. Chilton J, Chilton K. A critique of risk modeling and risk assessment of municipal landfills based on U.S. Environmental Protection Agency techniques. Waste Manag Res 10:505-516 (1992).
53. Brauch H-J, Kühn W, Werner P. Vinyl chloride in contaminated groundwater [in German]. Vom Wasser 68:23-32 (1987) .
54. Milde G, Nerger M, Mergler R. Biological degradation of volatile chlorinated hydrocarbons in groundwater. Water Sci Technol 20:67-73 (1988).
55 Wolf K, Holland R, Rjaratnam A. Vinyl chloride contamination: the hidden threat. J Hazard Mater 15:163-184 (1987).
56. Dieter HH, Kerndorff H. Presence and importance of organochlorine solvents and other compounds in Germany's groundwater and drinking water. Ann Ist Super Sanita 29:263-277 (1993).
57. Semprini L, Kitanidis PK, Kampbell DH, Wilson JT. Anaerobic transformation of chlorinated aliphatic hydrocarbons in a sand aquifer based on spatial chemical distributions. Water Resour Res 31:1051-1062 (1995).
58. Lesage S, Jackson RE, Priddle MW, Riemann PG. Occurrence and fate of organic solvent residues in anoxic groundwater at the Gloucester Landfill, Canada. Environ Sci Technol 24:559-566 (1990).
59. Parsons F, Wood PR, DeMarco J. Transformations of tetrachloroethene and trichloroethene in microcosms and groundwater. J Am Water Works Assoc 76:56-59 (1984).
60. Vogel TM, McCarty PL. Biotransformation of tetrachloroethylene to trichloroethylene, dichloroethylene, vinyl chloride, and carbon dioxide under methanogenic conditions. Appl Environ Microbiol 49:1080-1083 (1985).
61. McCarty PL. Biotic and abiotic transformations of chlorinated solvents in ground water. In: Symposium on Natural Attenuation of Chlorinated Organics in Ground Water. EPA 540/R-96/509. Washington, DC:U.S. Environmental Protection Agency, 1996;5-9.
62. McCarty PL. Breathing with chlorinated solvents. Science 276:1521-1522 (1997).
63. Freedman DL, Gossett JM. Biological reductive dechlorination of tetrachloroethylene and trichloroethylene to ethylene under methanogenic conditions. Appl Environ Microbiol 55:2144-2151 (1989).
64. DiStefano TD, Gossett JM, Zinder SH. Reductive dechlorination of high concentrations of tetrachloroethene to ethene by an anaerobic enrichment culture in the absence of methanogenesis. Appl Environ Microbiol 57:2287-2292 (1991).
65. De Bruin WP, Kotterman MJJ, Posthumus MA, Schraa G, Zehnder AJB. Complete biological reductive transformation of tetrachloroethene to ethane. Appl Environ Microbiol 58:1996-2000 (1992).
66. Major DW, Hodgins WW, Butler BJ. Field and laboratory evidence of in situ biotransformation of tetrachloroethene to ethene and ethane at a chemical transfer facility in North Toronto. In: Onsite Bioreclamation (Hinchee RE, Otfenbuttel RF, eds). Stoneham, MA:Butterworth-Heinemann, 1991;147-171.
67. Major D, Cox E, Edwards E, Hare P. Intrinsic dechlorination of trichloroethene to ethene in a bedrock aquifer. In: Intrinsic Bioremediation (Hinchee RE, Wilson JT, Downey DC, eds). Columbus, OH:Battelle Press, 1995;197-203.
68. Fiorenza S, Hockman EL, Szojka S, Woeller RM, Wigger JW. Natural anaerobic degradation of chlorinated solvents at a Canadian manufacturing plant. In: Bioremediation of Chlorinated and Polycyclic Aromatic Hydrocarbon Compounds (Hinchee RE, Leeson A, Semprini L, Ong SK, eds). Boca Raton, FL:Lewis Publishers, 1994;277-286.
69. Lee MD, Mazierski PF, Buchanan RJ, Ellis DE, Sehayek LS. Intrinsic in situ anaerobic biodegradation of chlorinated solvents at an industrial landfill. In: Intrinsic Bioremediation (Hinchee RE, Wilson JT, Downey DC eds). Columbus, OH:Battelle Press, 1995;205-222.
70. Weaver JW, Wilson JT, Kampbell DH. Extraction of degradation rate constants from the St. Joseph, Michigan, trichloroethene site. In: Symposium Proceedings on Natural Attentuation of Chlorinated Organics in Ground Water.EPA/540/R-96/509. Washington, DC:U.S. Environmental Protection Agency, 1996;69-73.
71. Ellis DE, Lutz EJ, Klecka GM, Pardiek DL, Salvo JJ, Heitkamp MA, Gannon DJ, Mikula CC, Vogel CM, Sayles GD, et al. Remediation technology development forum intrinsic remediation project at Dover Air Force Base, Delaware. In: Symposium on Natural Attentuation of Chlorinated Organics in Ground Water. EPA/540/R-96/509. Washington, DC:U.S. Environmental Protection Agency, 1996;93-97.
72. Dolan ME, McCarty PL. Small-column microcosm for assessing methane-stimulated vinyl chloride transformation in aquifer samples. Environ Sci Technol 29:1892-1897 (1995).
73. Jain MK, Criddle CS. Metabolism and cometabolism of halogenated C-1 and C-2 hydrocarbons. Prog Ind Microbiol 32:65-102 (1995).
74. Semprini L. In situ bioremediation of chlorinated solvents. Environ Health Perspect 103:101-105 (1995).
75. Holliger C, Schraa G, Stams AJM, Zehnder AJB. A highly purified enrichment culture couples the reductive dechlorination of tetrachloroethene to growth. Appl Environ Microbiol 59:2991-2997 (1993).
76. Sharma PK, McCarty PL. Isolation and characterization of a facultatively aerobic bacterium that reductively dehalogenates tetrachloroethene to cis-1,2-dichloroethene. Appl Environ Microbiol 62:761-765 (1996).
77. Maymó-Gatell X, Chien YT, Gossett JM, Zinder SH. Isolation of a bacterium that reductively dechlorinates tetrachloroethene to ethene. Science 276:1568-1571 (1997).
78. Meier T. Small helpers with a big impact; bacteria for cleaning wastegases containing vinyl chloride [in German]. Entsorgungs-Technik 6:41-44 (1994) .
79. Sachsen-Anhalt train accident with resulting fire and considerable danger to the area--dangerous goods train accident on 1 June 1996 in Schönebeck/Elbe Preliminary report to Ministry of Home Affairs [in German]. Sachsen-Anhalt, Germany:Heyrothsberge, 1996.
80. Hahn A, Michalak H, Begemann K, Heinemeyer G, Gundert-Remy U. Transportation accident with vinyl chloride. Health effects in 325 victims [in German]. Umweltmed Forsch Prax 3:144-155 (1998).
81. Hüttner E, Nikolova T. Cytogenetic analysis of peripheral lymphocytes in a population exposed to vinyl chloride through an accidental release into the environment. Toxicol Lett 96,97:143-148 (1998).
82. Zhao M-Y, Ying C-J, Shao N, Yang Y, Yang C-F, Shi L, Liu W-Q. The study of health effects of vinyl chloride air pollution on population. Biomed Environ Sci 7:136-143 (1994).
83. ATSDR. Toxicological Profile for Vinyl Chloride. Altanta, GA:Agency for Toxic Substances and Disease Registry, 1997.
84. Holm L, Westlin A, Holmberg B. Technical control measures in the prevention of occupational cancer: an example from the PVC industry. In: Proceedings of the International Symposium on the Prevention of Occupational Cancer. Geneva:International Labour Office, 1982;538-546.
85. Szadkowski D, Lehnert G, eds. Vinyl Chloride as a Cause of Disease: A Bibliography [in German]. Frankfurt, Germany:Verband Kunststofferyeugende Industrie e V., 1982;1-20.
86. Barnes AW. Vinyl chloride and the production of PVC. Proc R Soc Med 69:277-281 (1976).
87. Purchase IFH, Stafford J, Paddle GM. Vinyl chloride: an assessment of risk of occupational exposure. Food Chem Toxicol 25:187-202 (1987).
88. Anderson D, Richardson CR, Weight TM, Purchase IFH, Adams WGF. Chromosomal analyses in vinyl chloride exposed workers. Results from analysis 18 and 42 months after initial sampling. Mutat Res 79:151-162 1980).
89. Wu W, Steenland K, Brown D, Wells V, Jones J, Schulte P, Halperin W. Cohort and case-control analyses of workers exposed to vinyl chloride: an update. J Occup Med 31:518-523 (1989).
90. Hozo I, Andelinovic S, Ljutic D, Miric D, Bojic L, Gasperic I. Vinyl chloride monomer exposure by the plastic industry workers--basic condition for liver angiosarcoma appearance. Medicinski Arhiv 50:9-14 (1996).
91. Wang YL, Zhao XH. Occupational health of working women in China. Asia-Pacific J Public Health 1(4):66-71 (1987).
92 Fucic A, Horvat D, Dimitrovic B. Localization of breaks induced by vinyl chloride in the human chromosomes of lymphocytes. Mutat Res 243:95-99 (1990).
93. Hozo I. Croation cases of ASL [Abstract]. Presented at the Association of Plastics Manufacturers in Europe, 4-5 June 1998, Oslo, Norway.
94. Rashad MM, El-Belbessy SF, Hussein NG, Helmey MH, El-Toukhy MA. Effect on some enzyme activities of occupational exposure to vinyl chloride monomer for five consecutive years. Med Sci Res 22:289-290 (1994).
95. Viinanen R. Monitoring results of VC in a PVC plant in 1981-1993. Neste Research Report 93025T. Porvoo, Finland:Neste, 1993;1-13.
96. Pirastu R, Bellis S, Bruno C, Maltoni C, Masina A, Reggiani A. The mortality among the workers of vinyl chloride in Italy [in Italian]. Med Lav 82:388-423 (1991).
97. Studniarek M, Durski K, Liniecki J, Brykalski D, Poznanska A, Gluszcz M. Effects of vinyl chloride on liver function of exposed workers, evaluated by measurements of plasma clearance of the 99mTc-N-2,4-dimethylacetanilido-iminoiacetate complex. J Appl Toxicol 9:213-218 (1989).
98. Dobecki M, Romanowicz B. Occupational exposure to toxic substances during the production of vinyl chloride and chlorinated organic solvents [in Polish]. Med Pr 44:99-102 (1993).
99. Gáliková E, Tomíková K, Zigová A, Mesko D, Buchancová J, Petrisková J, Luptáková M, Jakubis M, Karaffová N. General health of workers in the Nováky chemical works exposed to vinyl chloride. Pracov Lék 46:251-256 (1994).
100. Du C-L, Chan C-C, Wang J-D. Comparison of personal and area sampling strategies in assessing workers' exposure to vinyl chloride monomer. Bull Environ Contam Toxicol 56:534-542 (1996).
101. Elliott P, Kleinschmidt I. Angiosarcoma of the liver in Great Britain in proximity to vinyl chloride sites. Occup Environ Med 54:14-18 (1997).
102. Falk H, Creech JL Jr, Heath CW Jr, Johnson MN, Key MM. Hepatic disease among workers at a vinyl chloride polymerization plant. JAMA 230:59-63 (1974).
103. Forman D, Bennett B, Stafford J, Doll R. Exposure to vinyl chloride and angiosarcoma of the liver: a report of the register of cases. Br J Ind Med 42:750-753 (1985).
104. Lee FI, Smith PM, Bennett B, Williams DM. Occupationally related angiosarcoma of the liver in the United Kingdom (1972-1994). Gut 39:312-318 (1996).
105. Association of Plastics Manufacturers in Europe. Unpublished data.
106. Lelbach WK. A 25-year follow-up study of heavily exposed vinyl chloride workers in Germany. Am J Ind Med 29:446-458 (1996).
107. Riordan SM, Loo CK, Haber RW, Thomas MC. Vinyl chloride related hepatic angiosarcoma in a polyvinyl chloride autoclave cleaner in Australia. Med J Aust 155:125-128 (1991).
108. Hayashi H, Sakamuto N, Aoi T, Fukumura A, Mano H, Inagaki T. Invasive character of malignant endothelial cells in vinyl-chloride-induced liver angiosarcoma. Nagoya J Med Sci 52:13-17 (1990).
109. Paliard P, Valette PJ, Berger F, Contassot JC, Partensky C. Péliose hépatique tardive après traitement d'un angiosarcomehépatique chez un sujet exposé au chlorure de vinyl monomère. Gastroenterol Clin Biol 15:445-448 (1991).
110. Neshiwat LF, Friedland ML, Schorr-Lesnick B, Feldman S, Glucksman WJ, Russo RD. Hepatic angiosarcoma. Am J Med 93:219-222 (1992).
111. Hozo I, Andelinovic S, Ljutic D, Bojic L, Miric D, Giunio L. Two new cases of liver angiosarcoma: history and perspectives of liver angiosarcoma among plastic industry workers. Toxicol Ind Health 13:639-647 (1997).
112. Wong O, Whorton MD, Foliart DE, Ragland D. An industry-wide epidemiologic study of vinyl chloride workers, 1942-1982. Am J Ind Med 20:317-334 (1991).
113. Simonato L, L'Abbé KA, Andersen A, Belli S, Comba P, Engholm G, Ferro G, Hagmar L, Langard S, Lundberg I, et al. A collaborative study of cancer incidence and mortality among vinyl chloride workers. Scand J Work Environ Health 17:159-169 (1991).
114. Chemical Manufacturers Association. Unpublished data.
115. International Agency for Research on Cancer. Unpublished data.
116. Pirastu R, Chellini E, Carnevale F, De Santis M, Bracci C, Comba P. Cohort mortality study of vinyl chloride exposed workers in Porto Marghera during production, polymerization and bagging [in Italian]. Rapporti ISTISAN 97/22 39. Roma:Istituto Superiore di Sanità, 1997.
117. Pirastu R, Bruno C, De Santis M, Comba P. Cohort mortality study of vinyl chloride exposed workers in Ferrara, Rosignano and Ravenna. Epidemiol Prev 22:226-236 (1999).
118. Bartsch H, Barbin A, Marion MJ, Nair J, Gu Y. Formation, detection and role in carcinogenesis of ethenobases in DNA. Drug Metab Rev 26:349-371 (1994).
119. Bolt HM. Vinyl halides, haloaldehydes and nonohaloalkanes. IARC Sci Publ 125:141:141-150 (1994).
120. Barbin jA. Formation of DNA etheno adducts in rodents and humans and their role in carcinogenesis. Acta Biochim Pol 45:145-161 (1998).
121. Barbin A. The role of etheno DNA adducts in carcinogenesis induced by vinyl chloride in rats. IARC Sci Publ 150:303-313 (1999).
122. Giri AK. Genetic toxicology of vinyl chloride--a review. Mutat Res 339:1-14 (1995)
123. Ciroussel F, Barbin A, Eberle G, Bartsch H. Investigations on the relationship between DNA ethenobase adduct levels in several organs of vinyl chloride-exposed rats and cancer susceptibility. Biochem Pharmacol 39:1109-1113 (1990).
124. Grollman AP, Shibutani S. Mutagenic specifity of chemical carcinogens as determined by studies of single DNA adducts. IARC Sci Publ 125:385-397 (1994).
125. Cheng KC, Preston BD, Cahill DS, Dosanjh MK, Singer B, Loeb LA. The vinyl chloride DNA derivative N2,3-ethenoguanine produces G A transitions in Escherichia coli. Proc Natl Acad Sci USA 88:9974-9978 (1991).
126. Moriya M, Zhang W, Johnson F, Grollman AP. Mutagenic potency of exocyclic DNA adducts: marked differences between Escherichia coli and simian kidney cells. Proc Natl Acad Sci USA 91:11899-11903 (1994).
127. Basu AK, Wood ML, Niedernhofer LJ, Ramos LA, Essigmann JM. Mutagenic and genotoxic effects of three vinyl chloride-induced DNA lesions: 1,N6-ethenoadenine, 3,N4-ethenocytosine, and 4-amino-5-(imidazol-2-yl)imidazole. Biochemistry 32:12793-12801 (1993).
128. Pandya GA, Moriya M. 1,N6-ethenodeoxyadenosine, a DNA adduct highly mutagenic in mammalian cells. Biochemistry 35:11487-11492 (1996).
129. Eberle G, Barbin A, Laib RJ, Ciroussel F, Thomale J, Bartsch H, Rajewsky MF. 1,N6-etheno-2'-deoxyadenosine and 3,N4-etheno-2'-deoxycytidine detected by monoclonal antibodies in lung and liver DNA of rats exposed to vinyl chloride. Carcinogenesis 10:209-212 (1989).
130. Fedtke N, Boucheron JA, Walker VE, Swenberg JA. Vinyl chloride-induced DNA adducts. II: Formation and persistance of 7-(2'-oxoethyl)guanine and N2,3-ethenoguanine in rat tissue DNA. Carcinogenesis 11:1287-1292 (1990).
131. Swenberg JA, Fedtke N, Ciroussel F, Barbin A, Bartsch H. Etheno adducts formed in DNA of vinyl chloride-exposed rats are highly persistent in liver. Carcinogenesis 13:727-729 (1992).
132. El Ghissassi FE, Barbin A, Nair J, Bartsch H. Formation of 1,N6-ethenoadenine and 3,N4-ethenocytosine by lipid peroxidation products and nucleic acid bases. Chem Res Toxicol 8:278-283 (1995).
133. Chung FL, Chen HJC, Nath RG. Lipid peroxidation as a potential endogenous source for the formation of exocyclic DNA adducts. Carcinogenesis 17:2105-2111 (1996).
134. Guichard Y, El Ghissassi F, Nair J, Bartsch H, Barbin A. Formation and accumulation of DNA ethenobases in adult Sprague-Dawley rats exposed to vinyl chloride. Carcinogenesis 17:1553-1559 (1996).
135. Hollstein M, Marion M-J, Lehman T, Welsh J, Harris CC, Martel-Planche G, Kusters I, Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15:1-3 (1994).
136. Boivin S, Pedron S, Bertrand S, Desmouliere A, Martel-Planche G, Bancel B, Montesano R, Trepo C, Marion MJ. Myofibroblast-like cells exhibiting a mutated p53 gene isolated from liver human tumor of a worker exposed to vinyl chloride. In: Cells of the Hepatic Sinusoid (Wisse E, Knook DL, Balabaud C, eds). Leiden, The Netherlands:Kupffer Cell Foundation, 1997;449-451.
137. Barbin A, Forment O, Boivin S, Marion M-J, Belpoggi F, Maltoni C, Montesano R. p53 gene mutation pattern in rat liver tumors induced by vinyl chloride. Cancer Res 57:1695-1698 (1997).
138. Marion M-J, Froment O, Trépo C. Activation of Ki-ras gene by point mutation in human liver angiosarcoma associated with vinyl chloride exposure. Mol Carcinog 4:450-454 (1991).
139. Marion MJ, De VI, Smith S, Luo JC, Brandt RP. The molecular epidemiology of occupational carcinogenesis in vinyl chloride exposed workers. Int Arch Occup Environ Health 68:394-398 (1996).
140. DeVivo I, Marion M-J, Smith SJ, Carney WP, Brandt-Rauf PW. Mutant c-Ki-ras p 21 protein in chemical carcinogenesis in humans exposed to vinyl chloride. Cancer Causes Control 5:273-278 (1994).
141. Froment O, Boivin S, Barbin A, Bancel B, Trepo C, Marion M-J. Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res 54:5340-5345 (1994).
142. Boivin-Angèle S, Lefrancois L, Froment O, Spiethoff A, Bogdanffy MS, Wegener K, Wesch H, Barbin A, Bancel B, Trèpo C, et al. Ras gene mutations in vinyl chloride-induced liver tumors are carcinogen-specific but vary with cell type and species. Int J Cancer 85:223-227 (2000).
143. Clewell HJ, Gentry PR, Gearhart JM, Allen BC, Andersen ME. The Development and Validation of a Physiologically Based Pharmacokinetic Model for Vinyl Chloride and Its Application in a Carcinogenic Risk Assessment for Vinyl Chloride. ICF Kaiser report prepared for EPA/OHEA and OSHA/DHSP, 1995.
144. Chen CW, Blancato JN. Incorporation of biological information in cancer risk assessment: example-vinyl chloride. Cell Biol Toxicol 5:417-444 (1989).
145. Gargas ML, Burgess RJ, Voisard DE, Cason GH, Andersen ME. Partition coefficients of low-molecular-weight volatile chemicals in various liquids and tissues. Toxicol Appl Pharmacol 98:87-99 (1989).
146. Clement International Corporation. Development and validation of methods for applying pharmacokinetic data in risk assessment Vol 5 (AAMRL-TR-90-072-). Ruston, LA:Clement International Corporation, 1990.
147. D'Souza RW, Andersen ME. Physiologically based pharmacokinetic model for vinylidene chloride. Toxicol Appl Pharmacol 95:230-240 (1988).
148. Crump KS. An improved procedure for low-dose carcinogenic risk assessment from animal data. J Environ Pathol Toxicol 5:339-348 (1984).
149. U.S. EPA. Health Effects Assessment Summary Tables (HEAST). EPA/540 R-97/036. Washington, DC:U.S. Environmental Protection Agency, Office of Solid Waste and Emergency Response, 1997.
150. Reitz RH, Gargas ML, Andersen ME, Provan WM, Green TL. Predicting cancer risk from vinyl chloride exposure with a physiologically based pharmacokinetic model. Toxicol Appl Pharmacol 137:253-267 (1996).
151. WHO. Vinyl Chloride. In: Guidelines for Drinking-Water Quality, Vol 2. Health Criteria and Other Supporting Information. 2nd ed. Geneva:World Health Organization, 1996;424-431.
Last Updated: June 2, 2000
If you have come to this page from an outside location click here to get back to mindfully.org